Anxiety, depression, and other mental health issues have risen astronomically during the last 2 years. We know that there is a direct connection between our gut and our brain. Dr. Mahmoud Ghannoum walks us through that connection and how we can all approach our physical and mental health in COVID times. 

A little bit about Dr. Ghannoum: Dr. Mahmoud Ghannoum is one of the world’s leading microbiome researchers and the scientist who named the mycobiome, our body’s fungal community. He lectures at many institutions globally, including the National Institutes of Health, on the microbiome and his breakthrough research on probiotics. He’s published over 400 papers on his research and has been cited over 20,000 times by other scientists. For over 25 years, he’s been funded by the NIH, who’ve provided Dr. Ghannoum with over $50 million in grant funding.

In this episode, we cover: 

What is the microbiome?
The difference between the mircobiome and the mycobiome?
How to test for gut health.
The order of operations in treating gut dysbiosis.
The connection between our gut health and our mental health.
COVID-19 Stress Syndrome and  our microbiome.
How microbiome health can predict depression.


Dr. Ghannoum's press release:
Microbiome is Key to Fighting Depression
Renowned Microbiome Scientist Mahmoud Ghannoum, PhD, FAAM, FIDSA Publishes “A Microbiome-Driven Approach to Combating Depression During the COVID-19 Pandemic” in Frontiers of Nutrition
LOS ANGELES (August 24 2021) — Mental health issues, especially those related to depressive disorders, have increased dramatically during the COVID-19 pandemic and with hopes for shining light on a new approach to combatting these issues, renowned Microbiome Scientist, Mahmoud Ghannoum, PhD., FAAM, FIDSA shares findings for rebalancing the microbiome to treat depression in a groundbreaking peer-reviewed article, “A Microbiome-Driven Approach to Combating Depression During the COVID-19 Pandemic” in Frontiers of Nutrition.
Prescriptions for anti-anxiety medication have increased by 34%, antidepressant prescriptions by 18.6% and common anti-insomnia drugs by 14.8%, according to the latest research. Moreover, clinical trials show between 30-40% of depressed patients do not respond to their first-line antidepressant treatment, with 70% never achieving complete remission of symptoms.

Find Dr. Ghannoum:
✓Microbiome reports podcast
✓BIOHM
✓Dr. Microbiome
Want to see who is coming on next and have the chance to submit questions? Join my private FB community.
ION* Gut Support: Get a FREE 3oz bottle with your purchase of a 32oz bottle using the code HOLISTICHOUSE. Make sure to put both items in your cart before checking out! The 3oz bottle isn't automatically added, you have to manually add it to your cart.

---

Support this podcast: https://anchor.fm/stephanie-center/support